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Abstract
Background To assess the prevalence and determinants of
non-adherence to topical hypotensive treatment in glaucoma
patients in order to support interventions targeting enhance-
ment of patient adherence.
Methods One-hundred and sixty-six glaucoma patients,
recruited by nationwide multi-stage sampling, filled in an
extensive and carefully developed questionnaire covering
various theoretically relevant determinants of patient adher-
ence which were categorized as psychosocial aspects, barriers
and skills.
Results Prevalence of self-reported non-adherence was
27.3%. Younger patients (<55 years of age) had a higher
risk of being non-adherent. Forgetfulness, unavailability of
eye drops and difficulties with holding the bottle above the
eye when applying the eye drops were the most cited reasons
for non-adherence. Fifty percent of the patients indicated that
they required more information on the correct administration
of eye drops. There was no association between non-
adherence and sex, level of education, type of insurance,
duration of disease or family history of glaucoma.
Conclusions Non-adherence to topical glaucoma medica-
tion is fairly common. Aids that minimize forgetfulness and
delivery systems facilitating the delivery of medications to
the eye could be considered to enhance patient adherence
before advancing to other therapies with additional risks
and costs.
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Introduction
Professionals agree upon the importance of adherence to
ocular hypotensive medication in the treatment of glaucoma
patients, to reduce the risk of visual impairment [1–5]. A
systematic review of 63 studies assessing the relation
between adherence and outcomes of medical treatments
showed that non-adherent patients have a greater risk of a
poor outcome than adherent patients [6]. Because poor
adherence can result in ineffectiveness of treatments,
improvement of adherence could prevent the need to
advance to more aggressive therapies. However, despite
the introduction of eye drops with fewer side effects and a
simpler medication regimen during the last years, still 10%
to 30% of glaucoma patients regularly omit prescribed
doses [3, 7–11]. Few studies have yet been done that
systematically assess the causes of deviation from medica-
tion regimen in glaucoma patients in order to improve
patient care. Taylor et al. used a qualitative methodology to
understand the motivation of 28 glaucoma patients not to
comply. Forgetfulness was the most reported reason for
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non-adherence [12]. Tsai et al. developed a systematic
classification of a wide range of potential obstacles to
adherence to glaucoma medication. Seventy-one barriers to
non-adherence were categorized into four groups: social/
environmental factors, patient factors, provider factors and
regimen factors [11]. Sleath et al. listed 13 problem areas,
and asked patients if they experienced one or more
problems with their glaucoma medications. Most reported
problems included practical difficulty with drop adminis-
tration, paying for medications and remembering to take the
medication [13]. Interventions for enhancing adherence
should be based on reasons for non-adherence, and should
be applicable in regular, daily care [14]. Our aim was to
quantitatively assess various relevant determinants of
adherence to topical glaucoma medication that could later
be addressed in an adherence-enhancing intervention.
Materials and methods
Patients
We conducted a cross-sectional multi-center study in the
Netherlands, in which we enrolled 166 adult patients who
were treated for primary open-angle glaucoma. Ethics
committee approval was obtained, and all persons gave
their informed consent before being included in the study.
No selection was made based on duration of the disease or
type of glaucoma medication used. Patients were recruited
by multi-stage sampling. We took a random sample of 60
ophthalmologists from the directory of the Dutch Ophthal-
mological Society. They were asked to invite four consec-
utive glaucoma patients to fill in a self-administered
questionnaire during their visit to the outpatient department.
In case a patient was not willing or unable to participate in
the study, the ophthalmologists were asked to select the
next consecutive patient. Selection bias was minimized by
asking four consecutive patients as, in this way, ophthal-
mologists could only select the first patient that they
thought to be appropriate for participation. We expected
that most ophthalmologists would be able to select a
maximum of four patients during one outpatient clinic,
and that workload was reduced by the selection of 60
ophthalmologists.
Based on a response rate of 50% and a target number of
100 patients, we planned to ask 200 patients to participate
in the study. The 95% confidence interval of a frequency of
one certain item would be: freq ± 1.96 × (freq × (1 – freq)/
n)1/2. With 100 responding patients and a frequency of
10%, the 95% confidence interval would have been 4%-
16%. With 100 responding patients and a frequency of
50%, the 95% confidence interval would have been 40%-
60%.
Questionnaire
Non-adherence was defined as the failure to take topical
hypotensive treatment as prescribed, i.e. the omission of
prescribed doses. We aimed to include in the questionnaire
all potential causes of non-adherence to glaucoma medica-
tion that were reported in the literature and that were put
forward by patients and experts. To select appropriate items
for the questionnaire, a systematic inventory of the relevant
literature was conducted and four focus-group interviews
with 21 glaucoma patients from four hospitals were held,
one of which was a university hospital. In focus group
patients, we made allowance for the duration of glaucoma
and membership of the Glaucoma Patient Society. The
duration of glaucoma in focus group patients ranged from
1 month to 22 years, and nine patients were members of the
Glaucoma Patient Society. Members of the Glaucoma
Patient Society were placed in one focus group, as well as
patients with a short duration of glaucoma. Reasons for not
mixing these patients with other patients included prevention
of dominance of some patient groups and the different level
of knowledge of members of the Glaucoma Patient Society
and patients with short duration of glaucoma compared to
other patients. In this way, we obtained a variety in patient
characteristics in the focus groups.
Experts in ophthalmology, patient education and phar-
macology reviewed the concept version of the question-
naire. In addition, we tested the questionnaire in a pilot
study with ten patients. Based on key determinants from
health education theory, we distinguished three clusters of
causes: psychosocial determinants of behavior (including
factors as for example attitude and social influence), barriers
(e.g. co-morbidity and understanding) and skills [15]. We
listed 34 possible determinants of non-adherence, consist-
ing of 18 psychosocial reasons, six barriers and ten skills.
Patients could fill in whether they had never missed an eye
drop, whether they had missed an eye drop once or whether
they had missed an eyedrop more than once because of the
stated reason.
To discover any supplementary topics that could lead to
better adherence if addressed in a patient education program,
we examined patients’ subjective need for information.
Therefore, we asked patients to indicate whether they
preferred much, some or no information about 22 listed items
concerning need for information.
Questions about the various causes of non-adherence
were formulated in plain Dutch. Questions covered the past
4 weeks in order to minimize the risk of recall bias.
Statistical analysis
In order to minimize data-entry errors, experienced data
typists entered the data twice and checked for discrep-
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ancies. If patients had not answered the question about how
often they had missed an eye drop during the past 4 weeks
(n=11), we classified them as adherent or non-adherent
according to the answers given to the questions concerning
causes of non-adherence. Four patients who claimed not to
have missed a single dose due to one of the reasons given
were classified as adherent. Three patients who had missed
an eye drop at least once due to one of the reasons given
were classified as non-adherent. Four patients whose status
of being adherent or non-adherent could not be determined
and eight patients who did not use eye drops for glaucoma
treatment at all were excluded from further analysis.
Statistical analyses were performed with 154 patients,
using the software package SPSS 10.1. The χ2-test for
independence of two nominal variables was employed to
examine differences in frequency distributions of categor-
ical variables between adherent and non-adherent patients.
A p-value of < 0.05 was used to indicate statistical
significance. Univariate logistic models were fitted per item
to calculate the odds ratio of being non-adherent.
Results
Sociodemographic determinants
The response among the ophthalmologists was 73% (44/
60). Of the 236 questionnaires we had handed out, 166
(70.3%) were returned. With respect to the patients, reasons
not to participate in the study were cognitive dysfunction,
language barriers and lack of time.
Table 1 shows the characteristics of the patients and
the prevalence of the omission of doses. Twenty-six
percent of the patients reported that they had missed an
eye drop once or more than once during the past 4 weeks.
After imputation, 27.3% of the patients were classified as
non-adherent.
There was a statistically significant difference (p=0.01)
in the proportion of adherent and non-adherent patients
between the different age groups (Table 2). The odds ratio
of being non-adherent was less in the higher age categories
compared to the lowest category (<54 years).
Table 1 Characteristics of the
study population and the prev-
alence of omission of doses
during the past four weeks
Data are mean (±SD) or num-
ber of patients (%).
a Health insurance for patients
belonging to higher income
categories.
b Health insurance for patients
belonging to lower and average
income categories.












f i.e.: not a single dose was
omitted.
Characteristics of the study population
Sex (n=153) Female 74 (48.4%)
Mean age (n=153) 64.5 (±12.9)
Educational level (n=153) Low 62 (40.5%)
Moderate 50 (32.7%)
High 41 (26.8%)
Health insurance (n=153) Privatea 56 (36.6%)
Dutch National Health Serviceb 91 (59.5%)
Dutch civil servant health insurancec 6 (3.9%)
Duration of glaucoma (n=145) ≤ 2 years 35 (24.1%)
Family members with glaucoma (n=151) Yes 56 (37.1%)
Do not know 38 (25.2%)
History of surgical or laser therapy (n=150) None 97 (64.7%)
Laser therapy 30 (20.0%)
Surgical treatment 5 (3.3%)
Both 18 (12.0%)
Prescribed medication (n=154)d Latanoprost 70 (45.5%)
Timolol 51 (33.1%)
Betaxolol 22 (14.3%)
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With respect to type of medication, differences in
proportion of adherent and non-adherent patients did not
reach statistical significance (p=0.06). The unadjusted odds
ratio for non-adherence in the patient group who received a
combination therapy (≥ 2 different bottles) was 3.3 (95% CI
[1.2; 9.6], p=0.02) with patients prescribed a beta-blocker
serving as reference group. There was no difference between
patients prescribed a beta-blocker and patients prescribed
latanoprost.
Patients who had undergone laser treatment seemed to be
at greater risk for non-adherence than patients who had
no history of surgical or laser treatment. However, this
association was not statistically significant.
There were no statistically significant differences in
proportion of adherent and non-adherent patients for sex,
level of education, type of insurance, duration of disease or
family history of glaucoma.
Psychosocial determinants, barriers and skills
The proportion of patients who admitted to having
forgotten to administer their eye drops once or more was
26.7% (39/146). Other psychosocial reasons were reported
by 0.7% to 4.2% of the patients (Table 3).
Twenty-three patients out of 145 (15.9%) reported that
they had omitted their medication once or more than once
because they did not have eye drops or gel with them
(Table 4). All other barriers were reported as a reason for
omission of eye drops by less than 5% of the patients.
Generally, difficulties with the correct administration of
eye drops were reported by a greater proportion of patients
as a reason for omission of doses than were psychosocial
causes or barriers (Table 4). Difficulties with holding the
bottle properly above their eye were most often reported
(16% of the patients).
Table 2 Non-adherence by
patient characteristics
a CI = confidence interval
b NHI = National Health
Insurance
c i.e. ≥2 different bottles







<55 y (n=38) 44.7 1
55–64 y (n=28) 35.7 0.7 (0.3–1.9)
65–74 y (n=50) 16.0 0.2 (0.1–0.6)
>74 y (n=37) 18.9 0.3 (0.1–0.8)
Sex 0.63
Male (n=79) 29.1 1
Female (n=74) 25.7 0.8 (0.4–1.7)
Educational level 0.70
Low (n=62) 24.2 1
Moderate (n=50) 28.0 1.2 (0.5–2.8)
High (n=41) 31.7 1.5 (0.6–3.5)
Insurance 0.61
Private/Civil servant (n=62) 29.0 1
NHIb (n=91) 25.3 0.8 (0.4–1.7)
Duration of disease 0.72
< 1 year (n=15) 26.7 1
1–2 years (n=20) 35.0 1.5 (0.3–6.4)
> 2–5 years (n=41) 22.0 0.8 (0.2–3.0)
> 5–10 years (n=37) 35.1 1.5 (0.4–5.6)
> 10 years (n=32) 28.1 1.1 (0.3–4.3)
Family members with glaucoma 0.96
Yes (n=56) 28.6 1
No (n=57) 26.3 0.9 (0.4–2.0)
Don’t know (n=38) 26.3 0.9 (0.4–2.3)
Medication 0.06
Beta blocker (n=48) 22.9 1
Xalatan (n=47) 21.3 0.9 (0.3–2.4)
Combinationc (n=24) 50.0 3.4 (1.2–9.6)
Other (n=35) 25.7 1.2 (0.4–3.2)
Surgery/laser treatment 0.08
None (n=97) 25.8 1
Laser only (n=30) 43.3 2.2 (0.9–5.2)
Surgery only/surgery + laser (n=23) 17.4 0.6 (0.2–2.0)
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n % n % n %
Psychosocial determinants
I forgot to take the eye drops (n=146) 107 73.3 23 15.7 16 11.0
I found putting eye drops in my eye to be such a nuisance (n=143) 137 95.8 2 1.4 4 2.8
I suffered from side-effects (n=144) 139 96.5 2 1.4 3 2.1
I did not consider my glaucoma serious enough (n=143) 138 96.5 4 2.8 1 0.7
I did not use the eye drops at certain points in time (n=147) 142 96.6 2 1.4 3 2.0
I thought they would do more harm than good (n=144) 140 97.2 1 0.7 3 2.1
I found using eye drops uncomfortable (n=143) 139 97.2 2 1.4 2 1.4
I thought that it would not help anyway (n=144) 141 97.9 1 0.7 2 1.4
I already had to take the eye drops so often (n=143) 140 97.9 2 1.4 1 0.7
I thought I would be able to do without eye drops or gel (n=142) 140 98.6 0 0.0 2 1.4
I used the eye drops when it suited me (n=143) 141 98.6 1 0.7 1 0.7
My glaucoma did not deteriorate (n=143) 141 98.6 0 0.0 2 1.3
I can still see well (n=143) 141 98.6 0 0.0 2 1.4
I did not consider it important to use the eye drops (n=143) 141 98.6 0 0.0 2 1.4
I thought that I did not have to use the eye drops because my eyes were giving me trouble (n=143) 141 98.6 0 0.0 2 1.4
I thought that I would not become blind anyway (n=141) 140 99.3 0 0.0 1 0.7
Because others did not consider it important (n=143) 142 99.3 0 0.0 1 0.7
Because my partner thought it to be unnecessary (n=143) 143 100.0







n % n % n %
Barriers
I did not have eye drops, gel or salve with me (n=145) 122 84.1 17 11.7 6 4.2
The eye drops, gel or salve had run out (n=147) 141 95.9 6 4.1 0 0.0
I suffered from another illness that prevented me from administering the eye drops properly (n=145) 142 97.9 3 2.1 0 0.0
I did not have anyone to assist me with administering the eye drops (n=145) 144 99.3 1 0.6 0 0.0
I did not know how often or at what time I had to use the eye drops (n=145) 144 99.3 1 0.7 0 0.0
I did not quite understand the prescription (n=144) 144 100.0
Skills
I was not able to hold the bottle properly above my eye (n=149) 125 83.9 12 8.1 12 8.1
I did not feel whether the drop landed in my eye (n=144) 128 88.9 8 5.6 8 5.6
I touched my eye with the bottle (n=145) 129 89.0 13 9.0 3 2.1
I could not see the bottle above my eye well (n=147) 132 89.8 8 5.4 7 4.8
I was not able to squeeze the bottle well (n=147) 137 93.2 5 3.4 5 3.4
I was not able to pull my eyelid down sufficiently (n=147) 139 94.6 4 2.7 4 2.7
I did not know well how to administer the eye drops properly (n=145) 143 98.6 2 1.4 0 0.0
I found it difficult to remove the cap from the bottle (n=145) 144 99.3 1 0.7 0 0.0
I could not hold the bottle well (n=146) 145 99.3 1 0.7 0 0.0
It was difficult to open the sealed bottles (n=145) 145 100.0
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Finally, 50% of the patients indicated that they would
like to receive more information on how to administer eye
drops correctly (data not shown).
Discussion
Non-adherence to topical hypotensive treatment continues
to be a considerable obstacle in the treatment of glaucoma
patients, despite the recent development of drugs with
relatively simpler treatments and fewer side-effects. In order
to make a thorough inventory of the theoretically relevant
determinants of non-adherence and their frequency distribu-
tion in glaucoma patients, we systematically developed an
extensive questionnaire, including questions on psychoso-
cial aspects, potential barriers and skills.
The systematically developed questionnaire, based on
focus group interviews, opinions of experts and a pilot test,
included various causes of non-adherence. As the questions
were formulated in plain Dutch and 95% of non-adherent
patients reported one or more causes of non-adherence,
socially acceptable responses are not expected. The risk of
recall bias was minimized by asking about the previous
4 weeks. Moreover, 29.7% of the questionnaires were not
returned for analysis, and it is not known whether patients
who refused to be included were adherent or non-adherent.
Possible bias in the interpretation of the data from this
ignorance cannot be excluded. Reasons suggested by
patients for not participating were cognitive dysfunction,
language barriers and lack of time. Incentives were included
for both the ophthalmologists and the patients to improve
participation, and all ophthalmologists were contacted by
telephone after 2 to 3 weeks and by mail after 6 to 8 weeks.
With regard to the selection of patients, it is difficult to assess
case order. As described earlier, selection bias was minimized
by asking ophthalmologists to invite four consecutive patients
to participate. It was the best method for reducing selection
bias when compared to the situation in which each ophthal-
mologist selects one patient, or when compared to alternative
methods that select patients in non-randomly selected hospi-
tals, during pharmacy visits or from members of the
Glaucoma Patient Society.
In this study, adherence was defined quite strictly as
missing an eye drop once or more. Different studies use
varying definitions of adherence and different assessment
methods. Several studies define adherence as strictly as we
did [11, 16–21]. Our result of 27.3% non-adherent patients
corresponds with those of other reports that used question-
naires [22, 23], pharmacy refill records [8, 24] or electronic
medication monitors [25] to assess adherence. Based on a
systematic review of 569 studies from 1948 to 1998,
involving 17 disease conditions, an average non-adherence
rate of 24.8% and a non-adherence rate of 27.4% was found
for eye disorders [26]. Although self-reported adherence is
a subjective measure of adherence, it has been shown to be
a much better measure of adherence than one believed
formerly. Adherence data assessed by electronic monitoring
and a medication diary were comparable in cancer patients
with pain [27]. In a comparison of various methods for
measuring adherence to HIV protease inhibitors, patients’
self-reported adherence showed relatively high and signif-
icant correlations with results from medication event
monitoring systems [28].
Our study shows that forgetfulness, unavailability of
medication and insufficient skills for the most part
contributed to the omission of doses. Side effects, social
influence, inconvenience of therapy or a negative attitude
towards the treatment only played a minor role. Further-
more, younger patients and those receiving a combination
therapy (≥2 different bottles) were significantly more
likely to be non-adherent.
Our findings are consistent with that of various studies
which report forgetfulness as one of the major causes cited
by glaucoma patients for the omission of prescribed doses
[3, 12, 17, 21, 29]. An intuitively obvious and often-cited
reason why glaucoma patients forget to take their eye drops
is that there is no immediate disability from the disease and
no direct advantage from the eye drops [5]. Non-acceptance
of the disease as well as the necessity of chronic treatment
may also be part of the cause. Tsai et al. categorized obstacles
to medication adherence. Forty-nine percent of obstacles
were categorized as social/environmental, 32% reflected
regimen factors, and 16% involved individual patient
factors. Only 3% of reported causes of non-adherence were
of medical provider origin [11].
Insufficient skills or a lack of manual dexterity in many,
especially older glaucoma patients or patients with co-
morbidities have been recognized by different researchers
[1, 3, 12, 13, 23, 30, 31]. Winfield et al. showed that
about half of patients experienced technical difficulties
with eye-drop administration, such as aiming, squeezing
and blinking [23]. They reported that 72% of patients
were never asked if they had any problems, and that 69%
would not report any problems to their doctor even if
asked [23]. Sleath et al. also showed that 44% of patients
experienced difficulty with drop administration, and 14%
of patients had trouble squeezing the bottle [13]. Our
study agrees with these findings, as it shows that many
patients are having difficulties in correctly administering
eye drops, and that many patients require information on
this issue.
Our result (that patients receiving a combination therapy
were less adherent) corresponds to findings of Robin et al.,
who reported a significant increase in refill intervals after
the addition of a second drug [32]. Moreover, Sleath et al.
found that patients using more glaucoma medications
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experienced problems with the application of their therapy
more often than patients taking fewer glaucoma medica-
tions [13]. Being treated with various topical medications at
the same time might be confusing for some, especially
older, patients, and seems an obvious reason for non-
adherence. A recently undertaken study has objectively
measured adherence by the use of electronic monitoring,
and found that poorer adherence was associated with more
complex regimens, although once-daily drugs in a complex
dosing regimen resulted in good adherence [33]. They
found a higher percentage of adherence than in our
findings, which could be explained by the fact that patients
in the study of Robin et al. were informed that their dosing
behavior was being monitored [33]. While some studies
suggest that reducing dose frequency will enhance adher-
ence [9, 34–36], it has also been reported that many patients
say that it would not make it easier to adhere to the
regimen, although it would be more convenient, and
patients prefer one drop once a day in terms of lifestyle
[11, 37, 38]. Stewart et al. reported that 74% of physicians
believed their patients would prefer once a day dosing, and
92% of physicians believed it would improve adherence.
However, only 20% of patients believed they would be
more adherent if they had a once a day dosing regimen
[37]. The same association seems to exist for side-effects.
Taylor et al. showed that only a few patients report non-
adherence because of side-effects, while a lot of patients
complain about them [12]. Jampel et al. show in a
willingness-to-pay analysis that patients place differing
value on certain eye-drop characteristics. Patients were
especially willing to pay more for eye drops that did not
produce blurring of vision, drowsiness or inhibition of
sexual performance. Patients were least willing to pay more
for reduction of dose frequency, and for a combination of
two medications in one bottle rather than two bottles [39].
We think that a drug regimen with lower dosing frequency
and fewer side-effects probably will not be the only
solution for the adherence problem.
In our study, patients younger than 55 years of age were
significantly less adherent than older patients. The working
situation of this younger group, which does not allow the
regular use of eye drops, or inconvenient effects such as
blurred vision that hinder people in doing their work, might
provide an explanation for this difference [29]. However,
this study was not designed to discover why younger
patients would be less adherent and no cause-effect
relationship can be concluded because of the cross-sectional
design of the study. An evidence-based review reported
nine studies that had investigated the relation between age
and non-adherence, and found that none of them reported
significant results [9].
The finding that patients who had undergone laser
therapy tended to be at higher risk of being non-adherent
has to be interpreted with caution. Since the underlying
study was cross-sectional, a cause-effect relationship cannot
be concluded. Patients who had undergone laser therapy
might be a selected group of non-adherent patients who had
undergone laser therapy because topical hypotensive
treatment was ineffective.
Several intervention studies have already tested the
effect of a memory aid [18, 19, 40] or an education and
tailoring program [41] on the prevalence of omission of
doses. These studies lacked different aspects of trial quality,
yet they all reported a small, but significant improvement of
patient adherence. However, there are no data available on
the effects of the different interventions in the long run, or
on the feasibility or cost-effectiveness of their implemen-
tation in daily clinical routine. Newer dosing aids combine
alarm features with a dosing lever, and register adherence
data [42, 43]. Others suggest written instructions as a
simple and inexpensive intervention, as written instructions
improved the accuracy of self-reporting medication regimen
[44]. Medication reviews are also seen as a tool for
improving adherence [45]. Systematic reviews have
shown that several types of intervention, such as technical,
educational, behavioral and combined interventions, are
effective in improving medication adherence in chronic
medical disorders, but the effect on clinical outcomes was
small [35, 36]. However, DiMatteo et al. and Hugen et al.
have shown that non-adherence increases the risk of poor
outcome of medical treatments [6, 28]. In general, the
most powerful intervention is believed to consist of a
combination of educational, behavioural and affective
components [46]. No single intervention appears to be
superior [47].
Although the present study has not proved it, we expect
that adherence-enhancing interventions should pay special
attention to the reduction of patient forgetfulness as well as
the improvement of medication administration skills. An
intervention focusing on other psychosocial determinants or
barriers seems unnecessary. In patients in whom the
intraocular pressure continues to be high, or progression
of visual field loss occurs despite the prescription of a
potent anti-glaucoma drug, patients’ skills in administering
eye drops should be checked, and the use of a dosing aid or
memory aid should be considered before turning to laser or
surgical therapy.
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